Comparing the current results to its competitors, Mannkind reported Revenue increase in the 2 quarter 2026 by 42.92 % year on year. The sales growth was above Mannkind's competitors' average revenue growth of 6.93 %, achieved in the same quarter.
Mannkind Corporation, slower than the average decrease reported by the company's competitors of -81.55 %. recorded a net loss and most of the company's competitors saw a decline in earnings by -81.55 %
Mannkind's Comment on Competition and Industry Peers
The company operates in the pharmaceutical and biotechnology industries, which are characterized by rapid technological advancements and intensive research and development. It competes with major global pharmaceutical companies and other institutions that possess greater financial resources, research and development capabilities, marketing and sales expertise, and more experience in preclinical and clinical testing, regulatory approvals, and biopharmaceutical product marketing. Competitors may develop products for the treatment of diabetes, heart failure, or other indications that are similar, more effective, better tolerated, or less costly. Key competitive factors include product efficacy and safety, regulatory approval timing and scope, ease of use, price, manufacturing, marketing success, recruitment and retention of qualified personnel, and clinical trial site establishment and patient enrollment. Specifically, Afrezza competes primarily with rapid-acting insulin analogs administered at the beginning of a meal.
Strong sales growth of 42.92 % in Overall company contributed to Mannkind Corporation increase in total revenue by 42.92 % Mannkind Corporation improved its market share in this segment, to approximately 0.14 %.
December 16, 2024
MannKind Corporation has recently made significant strides in the field of inhaled therapies, garnering attention with the announcement of encouraging six-month results from its Phase 3 trial investigating inhaled insulin, Afrezza, for pediatric patients with diabetes. This trial, known as INHALE-1, has shown potential in altering the management of diabetes in younger populations.The Phase 3 INHALE-1 trial focused on evaluating the efficacy and safety of Afrezza in children with type 1 diabetes. The study s six-month results revealed promising outcomes, indicating that Afrezza could be a viable alternative for managing blood glucose levels in pediatric patients. The inhaled formulation is designed to offer r...
June 5, 2024
Diabetes mellitus, a chronic condition characterized by hyperglycemia, necessitates continuous innovation in treatment modalities to optimize glycemic control and improve patient quality of life. Traditional subcutaneous insulin administration, while effective, is often associated with patient discomfort, adherence issues, and a complex regimen. Inhaled insulin presents a promising alternative, offering potentially improved compliance and ease of use. The INHALE-3 study, a pivotal clinical trial evaluating the efficacy and safety of inhaled insulin, has provided significant insights into this novel mode of insulin delivery. These findings were presented during a symposium at the American Diabetes Associatio...
March 11, 2024
INHALE-3 Study s Initial Meal Challenge Results Comparing Afrezza Head-to-Head with Multiple Daily Injections (MDI) and Insulin PumpsRecently, the INHALE-3 study released its initial meal challenge results, which compared the effectiveness of Afrezza, an inhalable insulin, with multiple daily injections (MDI) and insulin pumps. This groundbreaking study aims to provide valuable insights into the efficacy and convenience of different insulin delivery methods for patients with diabetes.Afrezza, developed by MannKind Corporation, is a revolutionary inhalable insulin that offers a faster onset of action and shorter duration compared to traditional injected insulin. The INHALE-3 study sought to determine how Afre...
Pfizer Inc operates as a global pharmaceutical company that focuses on researching, developing, manufacturing, and marketing innovative medicines. Its business model emphasizes significant investment in research and development to build a diverse portfolio of therapies across various therapeutic areas, while leveraging strategic alliances and collaborations to enhance commercialization and drive growth.
Pacira Biosciences Inc is a pharmaceutical company that focuses on the development and commercialization of non-opioid pain management products and treatments.
Puma Biotechnology Inc operates as a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for the treatment of cancer. Their business model revolves around identifying promising preclinical and clinical drug candidates, conducting rigorous research and development, and seeking regulatory approval for their products. Puma Biotechnology Inc strives to effectively market and distribute their approved therapeutics to provide patients with potentially life-saving treatment options.
Sources:
Mannkind Corporation’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Mannkind Corporation versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
